NUVB Q2 2026: revenue surges 556% to $31.7M; net loss widens 6.5% on non-operating costs

Filed August 6, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 7, 2025 · ~2 min read

Key Changes

• high

  Operating loss narrowed 20% to $51.0M, but net loss widened 6.5% to $62.8M (diluted EPS -$0.18) as $16.4M of non-operating/other costs offset operational improvement—the bottom-line change did not come from operations.

  MD&A: Operating Results & Non-Operating Items verify on EDGAR →
• high

  Raised $287.5M via 0.75% convertible notes due 2032 (including $37.5M greenshoe exercised in July 2026).

  MD&A: Financing & Notes: Convertible Debt verify on EDGAR →
• high

  Secured exclusive global safusidenib rights by adding Japan to the Daiichi Sankyo license (April 2026); announced two new studies in July 2026—a pivotal Phase 3 in grade 2 IDH1-mutant glioma outside the U.S. and a Phase 2 for vorasidenib-progressed patients in the U.S.

  MD&A: Safusidenib Development verify on EDGAR →